Neuralstem is a biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. Our lead asset, NSI-189, is a new chemical entity in Phase 2 clinical development for major depressive disorder (MDD). Our transplantational stem cell asset, NSI-566, is a spinal cord-derived neural stem cell line being tested in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). These product candidates are based on the companyâs proprietary neural stem cell technology. Source
No articles found.
Since the companyâs inception, Tetraphase has developed a robust antibiotics pla...
Since the companyâs inception, Tetraphase has...
ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdianÂŽ the wor...
ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufac...
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company...
Alimera Sciences (NASDAQ: ALIM), founded in Jun...
Aptose Biosciences is a clinical-stage biotechnology company developing personaliz...
Aptose Biosciences is a clinical-stage biotechn...
We are a leading science and technology company that delivers life-transforming me...
We are a leading science and technology company...
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering,...
Gossamer Bio is a clinical-stage biopharmaceuti...
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical c...
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a...
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and develop...
Aptinyx Inc. is a clinical-stage biopharmaceuti...
Founded in 1985, ENGlobal (NASDAQ: ENG) is a specialty engineering services firm t...
Founded in 1985, ENGlobal (NASDAQ: ENG) is a sp...
Join the National Investor Network and get the latest information with your interests in mind.